CN1896106A - 一种人血清白蛋白融合长效干扰素制备工艺 - Google Patents
一种人血清白蛋白融合长效干扰素制备工艺 Download PDFInfo
- Publication number
- CN1896106A CN1896106A CN 200610023785 CN200610023785A CN1896106A CN 1896106 A CN1896106 A CN 1896106A CN 200610023785 CN200610023785 CN 200610023785 CN 200610023785 A CN200610023785 A CN 200610023785A CN 1896106 A CN1896106 A CN 1896106A
- Authority
- CN
- China
- Prior art keywords
- interferon
- serum albumin
- fusion rotein
- yeast
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 43
- 102000014150 Interferons Human genes 0.000 title claims abstract description 43
- 229940079322 interferon Drugs 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims description 7
- 102000004506 Blood Proteins Human genes 0.000 title description 2
- 108010017384 Blood Proteins Proteins 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 13
- 230000004927 fusion Effects 0.000 claims description 35
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 28
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 20
- 108020004705 Codon Proteins 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 13
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 13
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 239000001166 ammonium sulphate Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 210000005253 yeast cell Anatomy 0.000 claims description 5
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 4
- 230000005611 electricity Effects 0.000 claims description 4
- 239000006052 feed supplement Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000012868 site-directed mutagenesis technique Methods 0.000 claims description 4
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 claims description 3
- 241000235648 Pichia Species 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 108060003552 hemocyanin Proteins 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000003016 phosphoric acids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010038049 Mating Factor Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150051118 PTM1 gene Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical group C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical group CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 101150026546 hsa gene Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610023785XA CN1896106B (zh) | 2006-02-07 | 2006-02-07 | 一种人血清白蛋白融合长效干扰素制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610023785XA CN1896106B (zh) | 2006-02-07 | 2006-02-07 | 一种人血清白蛋白融合长效干扰素制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1896106A true CN1896106A (zh) | 2007-01-17 |
CN1896106B CN1896106B (zh) | 2011-09-14 |
Family
ID=37608763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610023785XA Active CN1896106B (zh) | 2006-02-07 | 2006-02-07 | 一种人血清白蛋白融合长效干扰素制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1896106B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101818154A (zh) * | 2010-03-26 | 2010-09-01 | 华南农业大学 | 编码猪α、β或γ干扰素的基因片段及其应用 |
CN101062952B (zh) * | 2007-05-16 | 2011-07-27 | 中国人民解放军军事医学科学院生物工程研究所 | 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用 |
CN102199208A (zh) * | 2011-01-28 | 2011-09-28 | 武汉吉天朋生物科技发展有限公司 | 一种通用的载药系统及制备方法 |
CN102757502A (zh) * | 2011-04-27 | 2012-10-31 | 中国医学科学院病原生物学研究所 | 一种融合人白细胞介素28b及其制备方法 |
CN101664378B (zh) * | 2008-09-06 | 2012-11-21 | 浙江我武生物科技股份有限公司 | 一种重组人血清白蛋白与干扰素α融合蛋白的药物组合物 |
CN105504036A (zh) * | 2016-02-16 | 2016-04-20 | 齐鲁工业大学 | 一种具有强热稳定性的甜味蛋白monellin突变体及其制备方法 |
CN106282216A (zh) * | 2016-08-29 | 2017-01-04 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种重组长效鸡干扰素α的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1405181A (zh) * | 2001-08-10 | 2003-03-26 | 中国人民解放军军事医学科学院生物工程研究所 | 血清白蛋白与干扰素的融合蛋白 |
CN1269840C (zh) * | 2003-06-30 | 2006-08-16 | 美国福源集团 | 长效的人干扰素类似物 |
-
2006
- 2006-02-07 CN CN200610023785XA patent/CN1896106B/zh active Active
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062952B (zh) * | 2007-05-16 | 2011-07-27 | 中国人民解放军军事医学科学院生物工程研究所 | 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用 |
CN101664378B (zh) * | 2008-09-06 | 2012-11-21 | 浙江我武生物科技股份有限公司 | 一种重组人血清白蛋白与干扰素α融合蛋白的药物组合物 |
CN101818154A (zh) * | 2010-03-26 | 2010-09-01 | 华南农业大学 | 编码猪α、β或γ干扰素的基因片段及其应用 |
CN101818154B (zh) * | 2010-03-26 | 2012-12-26 | 华南农业大学 | 编码猪α干扰素的基因片段及其应用 |
CN102199208A (zh) * | 2011-01-28 | 2011-09-28 | 武汉吉天朋生物科技发展有限公司 | 一种通用的载药系统及制备方法 |
CN102199208B (zh) * | 2011-01-28 | 2013-06-05 | 武汉吉天朋生物科技发展有限公司 | 一种通用的载药系统及制备方法 |
CN102757502A (zh) * | 2011-04-27 | 2012-10-31 | 中国医学科学院病原生物学研究所 | 一种融合人白细胞介素28b及其制备方法 |
CN105504036A (zh) * | 2016-02-16 | 2016-04-20 | 齐鲁工业大学 | 一种具有强热稳定性的甜味蛋白monellin突变体及其制备方法 |
CN106282216A (zh) * | 2016-08-29 | 2017-01-04 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种重组长效鸡干扰素α的制备方法 |
CN106282216B (zh) * | 2016-08-29 | 2019-11-08 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种重组长效鸡干扰素α的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1896106B (zh) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1896106B (zh) | 一种人血清白蛋白融合长效干扰素制备工艺 | |
CN106220724B (zh) | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 | |
CN101525387B (zh) | 重组长效胰高血糖素样肽类似物及其制备方法 | |
CN101200503B (zh) | 血清白蛋白与干扰素的融合蛋白 | |
CN101514229B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物 | |
CN102286490B (zh) | 一种鸡干扰素γ的制备复性方法 | |
EP0656419A1 (en) | Method of highly purifying human serum albumin | |
CN103102418B (zh) | 粒细胞集落刺激因子(G-CSF)及其突变体(mG-CSF)与人血清白蛋白第三结构域(3DHSA)的融合蛋白及应用 | |
CN112851791A (zh) | 一种新型fgf19类似物及其应用 | |
CN116554309A (zh) | 一种重组人源ⅲ型胶原蛋白及其制备方法和应用 | |
CN102660550B (zh) | 基因重组人胸腺素β4的制备方法 | |
CN1287124A (zh) | 重组天然和新型人胰岛素及其制备方法 | |
CN1177051C (zh) | 一种重组胸腺素α1的制备方法 | |
CN101544981A (zh) | 一种具有降血糖生物活性的苦瓜多肽基因工程制备方法及应用 | |
CN108794637A (zh) | 一种重组犬长效干扰素α及制备此长效干扰素的融合蛋白及其制备方法 | |
CN117304344B (zh) | 一种融合蛋白、表达该融合蛋白的重组菌株及其应用 | |
CN1291031C (zh) | 重组胸腺素α1的制备方法 | |
CN102827290A (zh) | 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白 | |
US20230407364A1 (en) | Long-acting recombinant interleukin-18 binding protein and production method and application thereof | |
CN103467604A (zh) | 一种睡眠肽融合蛋白及其应用 | |
CN102358897B (zh) | 重组人寡腺苷酸合成酶-1的制备方法 | |
CN107383202A (zh) | 一种由鸡白蛋白、鸡干扰素γ和鸡白细胞介素2组成的融合蛋白及其制备方法 | |
CN116355074A (zh) | 一种长效猫ω干扰素突变体及其制备方法和应用 | |
CN1451666A (zh) | 一种重组抗肿瘤侵袭转移的融合蛋白 | |
CN114836453A (zh) | 一种编码蛋白酶k的基因及表达蛋白酶k的菌株 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SINOBIO BIOTECH CO. Free format text: FORMER OWNER: JIANYUAN BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD., SHANGHAI Effective date: 20110617 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200433 8008-11, NO. 335, GUODING ROAD, YANGPU DISTRICT, SHANGHAI TO: 201203 ROOM 201, BUILDING 2, NO. 720, CAILUN ROAD, ZHANGJIANG HIGH-TECH. PARK, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110617 Address after: 201203 Shanghai Zhangjiang hi tech Park Cailun Road 2 Building No. 201 room 720 Applicant after: Sinobio Biotech Co. Address before: 200433 No. 335, National Road, Shanghai, Yangpu District 8008-11 Applicant before: Jianyuan Biological Science and Technology Co., Ltd., Shanghai |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210113 Address after: 215200 science and technology pioneer park complex building, Wujiang Economic Development Zone, Suzhou City, Jiangsu Province Patentee after: WUJIANG NOVOPROTEIN SCIENTIFIC Inc. Address before: 201203 Room 201, building 2, 720 Cailun Road, Zhangjiang hi tech park, Shanghai Patentee before: SHANGHAI XINBAINUO BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 215200 science and technology pioneer park complex building, Wujiang Economic Development Zone, Suzhou City, Jiangsu Province Patentee after: Suzhou inshore protein Technology Co.,Ltd. Address before: 215200 science and technology pioneer park complex building, Wujiang Economic Development Zone, Suzhou City, Jiangsu Province Patentee before: WUJIANG NOVOPROTEIN SCIENTIFIC Inc. |